Compare Stocks: MRNA, PHVS, and ABBV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$261.50 +0.6%	$254.23	$190.75 ▼ $267.47	$459.35B	0.29	4.42 million shs	4.23 million shs
MRNA Moderna	$150.81 -2.2%	$82.40	$22.28 ▼ $176.66	$61.59B	1.1	32.11 million shs	16.54 million shs
PHVS Pharvaris	$35.17 +0.7%	$34.67	$20.65 ▼ $38.13	$2.28B	-2.33	676,852 shs	319,625 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.14%	-2.14%	+3.40%	+19.62%	+23.60%
MRNA Moderna	+9.93%	-2.87%	+181.41%	+214.45%	+540.39%
PHVS Pharvaris	+0.92%	-6.18%	+7.08%	+15.89%	+61.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$261.50 +0.6%	$254.23	$190.75 ▼ $267.47	$459.35B	0.29	4.42 million shs	4.23 million shs
MRNA Moderna	$150.81 -2.2%	$82.40	$22.28 ▼ $176.66	$61.59B	1.1	32.11 million shs	16.54 million shs
PHVS Pharvaris	$35.17 +0.7%	$34.67	$20.65 ▼ $38.13	$2.28B	-2.33	676,852 shs	319,625 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.14%	-2.14%	+3.40%	+19.62%	+23.60%
MRNA Moderna	+9.93%	-2.87%	+181.41%	+214.45%	+540.39%
PHVS Pharvaris	+0.92%	-6.18%	+7.08%	+15.89%	+61.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$275.95	5.53% Upside
MRNA Moderna	2.17	Hold	$80.53	-46.60% Downside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	45.23% Upside

Current Analyst Ratings Breakdown

Latest MRNA, PHVS, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	MRNA Moderna	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/28/2026	MRNA Moderna	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold
8/28/2026	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/28/2026	MRNA Moderna	Bradesco Corretora Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/28/2026	MRNA Moderna	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$180.00
8/25/2026	MRNA Moderna	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/24/2026	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$48.00 ➝ $125.00
8/21/2026	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$40.00 ➝ $77.00
8/20/2026	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$298.00 ➝ $303.00
8/20/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$50.00 ➝ $150.00
8/20/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$39.00 ➝ $89.00

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	7.55	$15.45 per share	16.93	($3.33) per share	-78.53
MRNA Moderna	$2.21B	27.24	N/A	N/A	$16.93 per share	8.91
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	73.87	16.19	1.16	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)

Latest MRNA, PHVS, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.65%	+6.80%	195.48%	53 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Latest MRNA, PHVS, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/18/2026	ABBV AbbVie	quarterly	$1.73	2.83%	7/15/2026	7/15/2026	8/14/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
MRNA Moderna	0.09	2.29	2.18
PHVS Pharvaris	N/A	11.94	11.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
MRNA Moderna	75.33%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
MRNA Moderna	10.80%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
PHVS Pharvaris	30	65.41 million	N/A	Not Optionable

MRNA, PHVS, and ABBV Headlines

Recent News About These Companies

Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 48.7% in August

September 1 at 1:59 PM | marketbeat.com

Moore Capital Management LP Buys Shares of 44,001 Pharvaris N.V. $PHVS

September 1 at 5:44 AM | marketbeat.com

Alyeska Investment Group L.P. Purchases 281,829 Shares of Pharvaris N.V. $PHVS

September 1 at 3:03 AM | marketbeat.com

Deutsche Bank AG Purchases Shares of 53,469 Pharvaris N.V. $PHVS

August 29, 2026 | marketbeat.com

venBio Partners LLC Invests $160.57 Billion in Pharvaris N.V. $PHVS

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys 457,804 Shares of Pharvaris N.V. $PHVS

August 27, 2026 | marketbeat.com

525,750 Shares in Pharvaris N.V. $PHVS Purchased by Elmind Capital LP

August 26, 2026 | marketbeat.com

5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS

August 26, 2026 | marketbeat.com

105,528 Shares in Pharvaris N.V. $PHVS Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - What's Next?

August 25, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Hits New 12-Month High - What's Next?

August 21, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock

August 19, 2026 | insidertrades.com

Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares

August 18, 2026 | marketbeat.com

What is HC Wainwright's Forecast for Pharvaris Q3 Earnings?

August 18, 2026 | marketbeat.com

Research Analysts Issue Forecasts for Pharvaris Q4 Earnings

August 17, 2026 | marketbeat.com

Pharvaris (PHVS) Gets a Hold from Bank of America Securities

August 14, 2026 | theglobeandmail.com

Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says

August 13, 2026 | finance.yahoo.com

Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

August 13, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Given New $75.00 Price Target at Citizens Jmp

August 13, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High - What's Next?

August 13, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's What Happened

August 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRNA, PHVS, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$261.50 +1.51 (+0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$262.03 +0.52 (+0.20%)

As of 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Moderna NASDAQ:MRNA

$150.81 -3.46 (-2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$150.93 +0.12 (+0.08%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pharvaris NASDAQ:PHVS

$35.17 +0.24 (+0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$35.80 +0.63 (+1.79%)

As of 07:56 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRNA, PHVS, and ABBV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRNA, PHVS, and ABBV Earnings

Compare Dividends

Latest MRNA, PHVS, and ABBV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRNA, PHVS, and ABBV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRNA, PHVS, and ABBV Company Descriptions

AbbVie NYSE:ABBV

Moderna NASDAQ:MRNA

Pharvaris NASDAQ:PHVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRNA, PHVS, and ABBV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRNA, PHVS, and ABBV Earnings

Compare Dividends

Latest MRNA, PHVS, and ABBV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRNA, PHVS, and ABBV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRNA, PHVS, and ABBV Company Descriptions

AbbVie NYSE:ABBV

Moderna NASDAQ:MRNA

Pharvaris NASDAQ:PHVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools